Incorporating information about the newer GLP-1 RAs, additional head-to-head studies suggest similar A1C reductions between lixisenatide and exenatide twice daily while showing more weight loss with exenatide twice daily and less GI AEs with lixisenatide [Rosenstock et al
Wegovy is approved for chronic weight management, which affects which insurance benefits apply, while Ozempic is approved for type 2 diabetes, meaning the same medication can carry a very different price tag depending on the indication billed
Your provider needs to know your health history before recommending any injectable treatment
Metformin for cardiovascular protection, inflammatory bowel disease, osteoporosis, periodontitis, polycystic ovarian syndrome, neurodegeneration, cancer, inflammation and senescence: what is next